A Look at What’s Ahead in the Rapidly Growing Cell Therapy Landscape
February 26th 2021Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.
New Cancer Research Collaboration Seeks to Develop Targeted Radium Therapeutic
February 23rd 2021Pharmacy Times® interviewed J. David Robertson, PhD, director of University of Missouri Research Reactor, on a new collaboration with Advanced Accelerator Applications International to develop a targeted therapy for certain types of cancerous tumors.
Impact of New Once-monthly, Long-acting HIV Regimen on Patient Care
February 17th 2021Pharmacy Times® interviewed Susan Swindells, MD, of the University of Nebraska Medical Center, on the impact of the recently FDA-approved once-monthly, long-acting HIV regimen on how providers care for patients with the virus.
How the Federal Retail Pharmacy Program May Affect the COVID-19 Vaccination Rollout
February 12th 2021Pharmacy Times® interviewed Kurt Proctor, PhD, RPh, senior vice president of strategic initiatives at the NCPA, on how the Biden administration’s launch of the Federal Retail Pharmacy Program may affect the COVID-19 vaccination rollout.
The COVID-19 Pandemic May Change The Way Hospital Pharmacies Do Business
February 12th 2021Pharmacy Times® interviewed Kim White, MBA, vice president of Numerof & Associates, on how changes in business strategies in hospitals due to the COVID-19 pandemic may affect how hospital pharmacies conduct their business.
What President Biden’s Enactment of the Defense Production Act May Mean for Pharmacy
February 10th 2021Pharmacy Times® interviewed Alex Hontos, JD, partner at Dorsey & Whitney, on the executive order President Biden signed directing agencies to utilize the Defense Production Act, among other tools, to prioritize production of COVID-19 vaccines and material.